RP 517

Drug Profile

RP 517

Alternative Names: 99Tcm-RP517; RP517; Technetium-99m-RP517

Latest Information Update: 01 Jul 2011

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AnorMED; Bristol-Myers Squibb
  • Class Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 25 Nov 2005 Discontinued - Phase-I for Solid tumour diagnosis in USA (unspecified route)
  • 24 Mar 2000 Phase-I clinical trials for Solid tumour diagnosis in USA (unspecified route)
  • 09 Sep 1998 Preclinical development for Inflammation diagnosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top